Introduction
============

Gynecological malignancies, particularly ovarian cancer, cervical cancer and endometrial cancer, are serious medical conditions in women and have been leading causes of cancer mortality in recent years. However, the use of cancer markers for early and progressive detection remain lacking ([@b1-mmr-18-01-0230]). In addition, research has demonstrated that there are close associations across the three aforementioned types of cancer. It has been demonstrated that the progress and the development of the three aforementioned types of cancer are similar, which may be useful when diagnosing any one of these three cancer types. In the case of endometrial cancer, prior to the development of endometrial carcinoma, the endometrium undergoes progressive neoplastic alterations in a parallel fashion to the premalignant alterations observed in the cervix prior to the development of cervical carcinoma ([@b2-mmr-18-01-0230]). The rationale of oophorectomy in surgical management is that endometrial cancer may metastasize to the ovary, in which women with endometrial cancer are at risk for synchronous and metachronous ovarian cancer, and the source of estrogen may be eliminated by oophorectomy ([@b3-mmr-18-01-0230],[@b4-mmr-18-01-0230]). In cancer cells, oncogenic transformation is associated with major alterations in gene expression ([@b5-mmr-18-01-0230]). With the advent of large-scale screening of cancer genomes, hundreds of genes with alterations in different types of tumors from patients with cancer have been identified ([@b6-mmr-18-01-0230]--[@b10-mmr-18-01-0230]), which revealed that cancer is a complex disease caused by genetic alterations in multiple genes ([@b11-mmr-18-01-0230],[@b12-mmr-18-01-0230]). In order to elucidate the cancer marker genes and biological processes associated with each type of gynecological tumor, and the potential underlying mechanism of associations among gynecological tumors, the contribution of identified differentially expressed genes (DEGs) to the pathogenesis of gynecological tumors must be understood.

To analyze different DEGs, high-throughput experimental methods, including microarray analysis, have been widely used in a number of studies ([@b13-mmr-18-01-0230],[@b14-mmr-18-01-0230]). A vast quantity of microarray data has been produced and deposited in publicly-available data repositories, including the Gene Expression Omnibus (GEO) ([@b15-mmr-18-01-0230]). With the methods of integrated bioinformatics analysis, researchers have been able to advance the identification of genetic signatures. This may provide insights into the underlying biological mechanisms of the development of gynecological tumors.

Chung *et al* ([@b16-mmr-18-01-0230]) revealed that microRNA (miRNA)-200b/a is a direct transcriptional target of grainyhead like transcription factor 2, which is associated with development and overall survival in epithelial ovarian cancer. Halabi *et al* ([@b17-mmr-18-01-0230]) demonstrated that 41 genes, including matrix metalloproteinase (MMP)7 and tumor protein 53, were involved in the potential underlying mechanisms of ovarian cancer. Espinosa *et al* ([@b18-mmr-18-01-0230]) revealed that six genes encoding cyclin B2, cell-division cycle protein 20, protein regulator of cytokinesis 1, synaptonemal complex protein 2, nucleolar and spindle associated protein 1 and cyclin-dependent kinase inhibitor 2 belonging to the mitosis pathway, were potential markers for screening or therapeutic targets of cervical cancer. However, biomarkers which were identified in this way have had poor translation into actual clinical practices. Results have been non-concordant among studies due to small sample sizes. In addition, the studies into the associations of biomarker genes (driver genes) remain lacking among the different types of gynecological tumors.

A robust driver gene biomarker signature may be beneficial for the diagnosis and targeted treatment of gynecological tumors. In the present study, in order to identify a driver gene biomarker signature for the three types of gynecological tumors, data from the Metabolic Gene Rapid Visualizer database (MERAV, which is derived from GEO) was used ([@b19-mmr-18-01-0230]). In MERAV, microarrays were normalized together to eliminate systematic errors caused by different batch experiments.

The present study devised a target network for ovarian cancer, cervical cancer and endometrial cancer using the selected driver genes, and further investigated the identified DEGs via functional enrichment analysis, pathway enrichment analysis and protein-protein interaction (PPI) networks. In addition, the present study extracted clinical information of ovarian cancer, cervical cancer and endometrial cancer from The Cancer Genome Atlas (TCGA) data portal. Subsequently, driver genes in each type of cancer were analyzed. It was important to investigate the underlying mechanism of each gynecological tumor and whether the identified driver genes contributed to these diseases. Subsequently, a network was generated between the miRNAs and the identified driver genes, using the method of mining the Mir2 disease and Tarbase databases which provide information on miRNAs, diseases and the interactions between miRNAs and genes. Finally, the present study determined hub-genes and hub-miRNAs across the gynecological tumors to study the potential underlying mechanisms of the developments of gynecological tumors, which may shed light on different strategies for the design of biological targets for cancer therapies.

Materials and methods
=====================

### Identification of gene expression datasets

In the present study, DEGs were identified between normal tissues and tumors extracted from the MERAV database from the National Center for Biotechnology Information GEO database (MERAV, <http://merav.wi.mit.edu>). The experimental samples for the present study are presented in [Tables I](#tI-mmr-18-01-0230){ref-type="table"} and [II](#tII-mmr-18-01-0230){ref-type="table"}. The following information was extracted from each identified study: GEO accession number, sample type, number of cases and controls, and gene expression data. Studies in which the microarray data were uncertain were excluded. The experimental protocol for the present study is presented in [Fig. 1](#f1-mmr-18-01-0230){ref-type="fig"}.

### Integrated analysis of DEGs identified in the extracted databases

Information was extracted from the microarray datasets in MERAV which are presented in [Tables I](#tI-mmr-18-01-0230){ref-type="table"} and [II](#tII-mmr-18-01-0230){ref-type="table"}, respectively. Following the intersection of the microarray datasets, the DEGs were established between the normal and cancer tissues. In the present study, the degree of differential gene expression was measured by fold-change based on the Student\'s t-test. A fold-change value \>2 or \<0.5 and t-test P\<0.01 for a gene was considered to be significant. The differential expression analysis was conducted using the Linear Models for Microarray Data package in R ([@b20-mmr-18-01-0230]).

### Protein interaction network

The DEGs were subsequently applied to the Human Protein Reference Database ([@b21-mmr-18-01-0230]) (HPRD, [www.hprd.org](www.hprd.org)), to identify the more complex functional interactive driver genes of separate cancer types. Genes with interactions with each other were extracted from the DEGs as mentioned above (presented in [Tables III](#tIII-mmr-18-01-0230){ref-type="table"}--[X](#tX-mmr-18-01-0230){ref-type="table"}). The PPI network is a useful research tool for investigating the cellular networks of protein interactions, and was downloaded from the HPRD. Cancer-associated gene-gene interaction networks were constructed by mapping the DEGs into the HPRD PPI network for each cancer (cervix tumor, ovarian tumor and endometrium tumor). To make it easier to identify the driver genes, the present study calculated the lines attached to each node, which was defined as the degree of the node. The nodes that exhibited degrees ≥4 were defined as driver genes. The nodes whose degree was ≥4 were considered to serve more complex roles in the development of the diseases of interest. These nodes were then extracted for the PPI network ([Fig. 2](#f2-mmr-18-01-0230){ref-type="fig"}). The present study constructed a connected network which contained the driver genes across the three cancer types. Through this method, it was determined whether the driver genes of the separate cancer types had any interaction with each other. The networks were constructed using Cytoscape version 3.3.0 ([www.cytoscape.org](www.cytoscape.org)).

### miRNAs regulating gene network construction

The present study analyzed the association between miRNAs and the identified driver genes ([Fig. 3](#f3-mmr-18-01-0230){ref-type="fig"}). This process was performed by extracting a list of miRNAs which were associated with the type of cancer (cervical tumor, ovarian tumor or endometrial tumor) from the Mir2 Disease database ([www.mir2disease.org](www.mir2disease.org)) ([@b22-mmr-18-01-0230]). Following this step, a network was created regarding the regulatory associations between the miRNA and the specific driver gene of each type of cancer in order to identify the hub-miRNAs of the gynecological tumors. The associations of the regulation were extracted from Tarbase (diana.cslab.ece.ntua.gr/tarbase) ([@b23-mmr-18-01-0230]).

### Functional and pathway enrichment analysis

In order to assess the functional relevance of the aforementioned DEGs, a pathway analysis was created based on the Database for Annotation, Visualization and Integrated Discovery (DAVID) ([@b24-mmr-18-01-0230]). DAVID provides a useful tool to analyze large gene lists, including gene ontology (GO) and pathway analysis. DEGs in different diseases were applied to this database in order to detect potentially represented functions. GO-categories were organized based on the GO database ([@b25-mmr-18-01-0230]) ([www.geneontology.org](www.geneontology.org)). In addition, pathway analysis was based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database ([@b26-mmr-18-01-0230]) (genome.jp/kegg). Significant categories were identified by expression analysis systematic explorer scores, a modified Fisher\'s exact P-value. The threshold for significance for a category was considered to be P\<0.01, with \>4 genes for the corresponding term.

### Survival analysis

The present study used TCGA database to extract clinical information and gene expression profile information. At the start of the analysis, the expression values of each driver gene were listed, which were identified via the PPI network. To find the median level of gene expression, the samples were divided into two groups by median of expression (high expression group and low expression group). Additionally, the corresponding clinical information of each sample was extracted. Survival data representing time between initial diagnosis and mortality were downloaded directly from TCGA data portal ([tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp](tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp)) ([@b27-mmr-18-01-0230]). With this information, the present study was able to estimate the association between the identified driver genes of the three types of cancer mentioned above and the survival rates of patients. All analyses were conducted using custom-written code in R ([www.r-project.org](www.r-project.org)).

Results
=======

### Integrated analysis of multiple studies to establish the driver genes in cancer

There are multiple genes that contribute to the cause of the aforementioned cancer types and, therefore, no single gene is a determining factor in diagnosis. It was identified that each type of cancer was driven by different variations of genes that serve key roles during the development of pathology. However, no single gene may explain the heterogeneity of each type of cancer. In the case of cervical cancer, 186 genes in squamous cell carcinoma of the cervix ([Table III](#tIII-mmr-18-01-0230){ref-type="table"}), 107 genes in keratinized squamous cell carcinoma of the cervix ([Table IV](#tIV-mmr-18-01-0230){ref-type="table"}), 96 genes in cervical adenocarcinoma Grade 3 ([Table V](#tV-mmr-18-01-0230){ref-type="table"}), 133 genes in non-keratinized squamous cell carcinoma of the cervix ([Table VI](#tVI-mmr-18-01-0230){ref-type="table"}) and 203 genes in cervical adenocarcinoma Grade 2 ([Table VII](#tVII-mmr-18-01-0230){ref-type="table"}) were identified to be important. In addition, 120 genes and 76 genes were established, respectively, in adenocarcinoma of the ovary Grade 2 and Grade 3 ([Tables VIII](#tVIII-mmr-18-01-0230){ref-type="table"} and [IX](#tIX-mmr-18-01-0230){ref-type="table"}). A total of 168 genes were established in endometrial carcinoma ([Table X](#tX-mmr-18-01-0230){ref-type="table"}).

### Integrated PPI (protein-protein interactions) network construction

Based on the HPRD, the interaction network of the identified driver genes was constructed, which consisted of 101 nodes (genes that form associations) and 185 edges (biological association) ([Fig. 2](#f2-mmr-18-01-0230){ref-type="fig"}). Genes with a higher degree of association (degree ≥4) were observed to be larger in size, and included the genes CDK1, CAV1, ZBTB16, Jun proto-oncogene AP-1 transcription factor subunit (JUN), RAF1, RB1, minichromosome maintenance complex component 2 (MCM2), AR, ABL1, LMNA, FLNA, DCN, FYN, SMAD1, LRP1, PSEN1, EP300, CTNNB1, collagen type I α1 chain (COL1A1) and FOS. Through this method, it was identified that driver genes in each gynecological cancer have contact interactions.

### Comprehensive analysis of miRNA regulation and the selected driver genes

[Fig. 3](#f3-mmr-18-01-0230){ref-type="fig"} illustrates that certain miRNAs serve important roles in regulating the driver genes. In the present study, it was demonstrated that a number of miRNAs regulate separate networks \[for example the let7 family, miRNA (miR)-23b, miR-21, miR-214 and miR-218\]. miRNAs that were confirmed to be significant in cervical cancer, including let7c and let7b, are also found to be associated with the other two cancers in this study. This information may be important in establishing the connections between the three gynecological cancer types, which may be used in the development of targets for further research and diagnosis.

### Functional and pathway enrichment analysis

GO analysis revealed that the identified genes of cervical tumors, ovarian tumors and endometrial tumors were predominantly involved in the illustrated biological processes ([Fig. 4](#f4-mmr-18-01-0230){ref-type="fig"}). The top three significant biological processes of cervical cancer were 'mitotic cell cycle', 'cell cycle' and 'cell cycle process', while for ovarian cancer, the biological processes consisted of 'cell cycle process', 'cell cycle phase' and 'macromolecule metabolic process'. For the progression of endometrial cancer, the top three biological processes observed to be at fault for cancer progression were 'response to organic substance', 'regulation of cell proliferation' and 'skeletal system development'.

Using the method of pathway analysis, it was revealed that genes in cervical cancer were significantly enriched in 'cell cycle', 'pathways in cancer' and 'DNA replication'. Ovarian cancer was observed to be significantly enriched in 'MAPK signaling pathway', 'cell cycle' and 'oocyte maturation'. Endometrial cancer was observed to be significantly enriched in 'pathways in cancer', 'focal adhesion' and 'complement and coagulation cascades' ([Fig. 5](#f5-mmr-18-01-0230){ref-type="fig"}).

### Survival analysis of patients with gynecological tumor

[Fig. 6](#f6-mmr-18-01-0230){ref-type="fig"} illustrates the association between survival time and survival rate in the high and low expression groups. The genes MCM2, MMP2, COL1A1 and JUN are presented in the figure, and it was observed that the driver genes of the expression groups were able to divide each of the target cancer types into two groups, one of which contained the high expression group with the other containing the low expression group. Therefore, in order to determine whether the driver genes had a key role in the development of gynecological tumors and the connective function of separate cancer types, the present study aimed to identify the association between the target cancer driver genes and other types of gynecological cancer.

Discussion
==========

The principal challenge of high-throughput cancer genomics is to identify specific driver genes and the underlying mechanisms of carcinogenesis, apart from the vast quantity of heterogeneous genomic alteration data. Numerous studies have focused on identifying individual functional modules or pathways involved in cancer ([@b28-mmr-18-01-0230]--[@b30-mmr-18-01-0230]). Based on this methodology, the analysis of the present study focused specifically on DEGs in order to reveal the transcriptional responses of gynecological tumors. The results of this analysis suggested that the common biological processes of cancer of the cervix, ovary and endometrium were those involved in the cell cycle and the regulation of macromolecule metabolism.

The cell cycle is the progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication. Research has shown that interference with cell cycle components may lead to tumor formation ([@b31-mmr-18-01-0230]). Certain cell cycle inhibitors, including retinoblastoma protein and tumor protein 53 may mutate during replication, causing the cell to proliferate uncontrollably, ultimately resulting in a tumor. Furthermore, the proportion of active cell division in tumors is much higher compared with the rate in normal tissue.

To clarify the hub genes in ovarian cancer, cervical cancer and endometrial cancer, DEGs were predicted to be biomarkers for each cancer using PPI networks. It is considered that hub nodes are genes that are highly connected with other genes and have been predicted to serve key roles in numerous networks. In addition, highly connected hub genes were proposed to have a considerable role in biological development. Hub nodes have more complex interactions compared with those of other nodes, which indicates that they have pivotal roles in the underlying mechanisms of disease. In addition, certain identified biomarkers of each type of cancer were extracted from each network and these driver genes were placed into one PPI network with the duplication hub genes eliminated. Therefore, the particular hub genes of each gynecological cancer and the connection nodes across the three types of cancers may be identified. Accordingly, the identification of hub genes and hub connected genes involved in each gynecological cancer may lead to the discovery of the association across ovarian cancer, cervical cancer and endometrial cancer, and may lead to the development of effective diagnostic and therapeutic approaches.

In order to ascertain a causal association across the three types of gynecological cancer, the present study extracted clinical information and gene expression profile information from TCGA database, and used the hub connected genes identified in the PPI network to perform survival analysis. In the present study, four noteworthy genes were identified, including MCM2, MMP2, COL1A1 and JUN.

The present study demonstrated that MCM2 may serve a key role in cervical cancer. A poor prognosis was associated with lower expression. Furthermore, MCM2 was highly connected with ovarian cancer and endometrial cancer. The results suggested that MCM2 is a component of the DNA replication licensing complex, with a rich binding surface that directs multiple regulatory interactions of cancer significance, marking DNA replication origins during the G1 phase of the cell cycle for use in the subsequent S-phase. A deficiency of MCM2 results in death or morbidity in the absence of an overt tumor ([@b32-mmr-18-01-0230]). These processes of DNA replication have been studied and used as therapeutic targets. Simon and Schwacha ([@b33-mmr-18-01-0230]) suggested that MCM2 was a promising target for blocking the proliferation of cancerous and precancerous cells.

In the present study, MMP2 was identified to be essential in causing cervical cancer. MMPs are zinc-containing endopeptidases with an extensive range of substrate specificities. These enzymes are able to degrade various components of extracellular matrix (ECM) proteins. In photocarcinogenesis, degradation of the ECM is the initial step towards tumor cell invasion, to intrude in the basement membrane and the surrounding stroma that primarily comprises fibrillary collagens. Additionally, MMP2 is involved in angiogenesis, which promotes cancer cell growth and migration ([@b34-mmr-18-01-0230]).

COL1A1 and COL1A2 encode the α1 and α2 chains of type I collagen, respectively ([@b35-mmr-18-01-0230]). The primary constituents of the ECM are collagens, adhesive glycoproteins and proteoglycans ([@b36-mmr-18-01-0230]). Specific interactions between cells and ECM-mediated cell-surface-associated components and transmembrane molecules result in the control of cellular activities, including adhesion and migration ([@b37-mmr-18-01-0230]). Collagen is the primary component of the ECM, which serves pivotal roles in maintaining skin and vessel elasticity, and increasing cartilage lubricity ([@b38-mmr-18-01-0230]). Upregulation of type II collagen expression may contribute to ovarian cancer metastasis and biological processes, including cell proliferation, invasion and migration ([@b39-mmr-18-01-0230]). The oncogene JUN is the putative transforming gene of avian sarcoma virus 17, which is the most extensively studied protein of the activator protein-1 complex and is involved in numerous cell activities, including proliferation, apoptosis, survival, tumorigenesis and tissue morphogenesis. The present study identified that COL1A1 was important in ovarian cancer, which was highly connected with cervical and endometrial cancer. Therefore, COL1A1 and JUN may be potentially important associated genes of the three types of gynecological malignancies.

miRNAs are small noncoding regulatory RNAs that downregulate transcription by targeting specific mRNAs. Furthermore, the present study identified that certain miRNAs were highly associated with hub connected genes, including let7, which is one of the founding members of the miRNA family. This miRNA was first identified in *Caenorhabditis elegans*. Lee and Dutta ([@b40-mmr-18-01-0230]) identified six functional let7 target sites in the 3′-untranslated region of high mobility group AT-hook 2 (HMGA2), which reduced HMGA2 expression and cell proliferation in a lung cancer cell line. Using genome-wide mRNA expression analysis, Mi *et al* ([@b41-mmr-18-01-0230]) identified that miRNA let7B was downregulated in acute lymphoblastic leukemia (ALL) compared with acute myeloid leukemia (AML). Quantitative polymerase chain reaction analysis confirmed the downregulation of let7B in ALL samples compared with AML samples and normal controls.

The present study identified that let7a, let7b and let7c had strong connections with the hub genes and that these miRNAs may serve an important part of the potential mechanism, which may explain the connections across the hub genes.

Overall, the present study identified a number of DEGs associated with gynecological cancer, in addition to the functions and signaling pathways in which these genes were involved. Comprehensive network analyses of the dysregulated gene expression in gynecological cancers identified a series of hub genes and the connection genes across ovarian cancer, cervical cancer and endometrial cancer in a PPI network. Subsequently, this study confirmed the driver genes by survival analysis using the TCGA database. Comprehensive network analyses of miRNAs and connection driver genes identified certain miRNAs which may be potential therapeutic and prevention targets of gynecological cancer. In addition, the present study demonstrated the associations across the different gynecological cancers, which may be useful for identifying potential useful diagnostic markers and novel therapeutic targets. The results of this study may provide an insight into the underlying mechanism of the aforementioned gynecological cancers and may lead to further improvement in diagnosis and treatment of them.
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![Experimental protocol of the present study. DEG, differentially express genes; GO, gene ontology; MERAV, Metabolic Gene Rapid Visualizer database; TGCA, The Cancer Genome Atlas.](MMR-18-01-0230-g00){#f1-mmr-18-01-0230}

![Protein-protein interaction networks of the DEGs identified by integrated analysis of the microarray databases throughout cancer of the cervix, ovary or endometrium. Each cancer holds a number of DEGs. Driver genes were extracted from the DEGs, whose degree (the number of lines attached to each node) was ≥4. The orange dots represent cervical carcinoma, green dots represent ovarian carcinoma and blue dots represent endometrial carcinoma. Genes with a higher degree of association exhibit a larger node size. Each biological association (an edge) between two genes (nodes) was supported by at least one reference from the literature or information stored in the Human Protein Reference Database. DEGS, differentially expressed genes.](MMR-18-01-0230-g01){#f2-mmr-18-01-0230}

![Network construction of miRNAs to driver genes. The miRNA dataset was downloaded from the Mir2 Disease database ([www.mir2disease.org](www.mir2disease.org)). The miRNAs presented in the figure are associated with cancer of the cervix, ovary or endometrium. Triangular nodes represent miRNAs. Circular nodes represent genes. Orange dots represent cervical carcinoma, green dots represent ovarian carcinoma and blue dots represent endometrial carcinoma. The degree for each dot is represented by the size of the node. miRNA/miR, microRNA.](MMR-18-01-0230-g02){#f3-mmr-18-01-0230}

![(A) GO terms of cervical cancer driver genes. (B) GO terms of ovarian cancer driver genes. (C) GO terms of endometrial carcinoma driver genes. GO, gene ontology.](MMR-18-01-0230-g03){#f4-mmr-18-01-0230}

![(A) KEGG pathway functional annotation of cervical cancer driver genes. (B) KEGG pathway functional annotation of ovarian cancer driver genes. (C) KEGG pathway functional annotation of endometrial carcinoma driver genes. KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-18-01-0230-g04){#f5-mmr-18-01-0230}

![Survival analysis of the different cancer types using the representative driver genes. Survival data representing time between initial diagnosis and mortality were downloaded directly from TCGA data portal. The red line represents the high expression group and the blue line represents the low expression group. (A) Cervical hub-gene MCM2 in cervical cancer. high and low expression of MCM2 divided the samples into two groups, with 133 and 144 samples in each group, respectively. (B) Cervical hub-gene MMP2 in cervical cancer, whose high and low expression divided the group into two, with 142 and 142 samples in each group, respectively. (C) Ovarian hub-gene COL1A1 in cervical cancer, whose high and low expression divided the group into two, with 143 and 141 samples in each group, respectively. (D) Ovarian hub-gene JUN in cervical cancer, whose high and low expression divided the group into two, with 141 and 144 samples in each group, respectively. MCM2, minichromosome maintenance complex component 2; MMP2, matrix metalloproteinase 2; COL1A1, collagen type I α1 chain; TCGA, The Cancer Genome Atlas.](MMR-18-01-0230-g05){#f6-mmr-18-01-0230}

###### 

Datasets from the Metabolic Gene Rapid Visualizer database (cervix).

  Tissue type                                       Datasets
  ------------------------------------------------- ------------------------------------------------------------------
  Normal, n=4                                       GSM176135, GSM175833, GSM176130, GSM176140
  Tumor                                             
    Squamous cell carcinoma, n=5                    GSM152635, GSM277702, GSM46919, GSM102527, GSM152587
    Squamous cell carcinoma non-keratinizing, n=5   GSM179907, GSM46942, GSM76614, GSM152580, GSM203742
    Squamous cell carcinoma keratinizing, n=3       GSM117576, GSM152723, GSM152751
    Adenoma, n=6                                    GSM179956, GSM152667, GSM152719, GSM179853, GSM325835, GSM203622

###### 

Datasets from the Metabolic Gene Rapid Visualizer database (ovary and endometrium).

                   Datasets                            
  ---------------- ----------------------------------- ------------------------------
  Normal tissues   GSM175789                           GSM175777, GSM175778,
                   GSM176131                           GSM175779, GSM175780,
                   GSM176136                           GSM175781, GSM175783,
                   GSM176318                           GSM175784, GSM175785,
                                                       GSM176039, GSM176040,
                                                       GSM176041, GSM176043,
                                                       GSM176093, GSM176099,
                                                       GSM176127, GSM176137,
                                                       GSM176141, GSM176142,
                                                       GSM176144, GSM176146,
                                                       GSM176143, GSM176145,
                                                       
  Tissue type      Ovary serous adenocarcinoma, n=11   Endometrioid carcinoma, n=12
                                                       
  Tumors           GSM8897, GSM203626, GSM15267,       GSM102425, GSM117582,
                   GSM102445, GSM46831, GSM152577,     GSM117586, GSM117590,
                   GSM88973, GSM152581, GSM27769,      GSM88952, GSM88966,
                   GSM277737, GSM301703                GSM102469, GSM102492,
                                                       GSM53058, GSM88978,
                                                       GSM46923, GSM46937

###### 

Driver genes identified by integrated analysis of the microarray datasets (cervical squamous cell carcinoma).

  Gene                                                 
  --------- ---------- ---------- --------- ---------- ----------
  RB1       HTRA1      MTOR       CLDN5     NARF       PURA
  MCM7      KPNA2      PLSCR4     CYBA      NCAPD2     RBM8A
  MCM2      LMNB1      PRKD1      DCUN1D1   NCF4       RECK
  PLK1      MEIS1      PSMA5      DDAH2     NME4       REV3L
  AR        NCOA1      PSMB10     DMPK      NPLOC4     RFC3
  PPP1CA    PBX1       PSMB9      EPS8      NR2F1      RNF126
  ABL1      PIAS3      PSMD2      EXOSC5    NR2F2      RPA3
  LMNA      POLA2      RACGAP1    GABBR1    NRAS       RRM1
  PTN       PPP1R14A   RTN3       GAS6      NTF3       RRM2
  TRIP13    AXL        SNRPB      GCH1      NTRK2      SAT2
  CAV1      BUB1B      TOR1AIP1   GCHFR     NUB1       SDC2
  CDC20     CCL14      TUBA4A     GLRX3     NUP210     SEC24A
  CDC6      CCR5       UBTF       GMFB      NUP50      SELENBP1
  FLNA      COL4A5     USP6NL     GOLGA2    PAFAH1B3   SERBP1
  FXR2      CSNK1D     UTP3       HOXD13    PAK2       SH3BP5
  ZHX1      DBF4       ACTN4      ILK       PAM        SMC4
  CCNA2     DVL3       ADAM10     KANK1     PCGF2      SNRPD1
  DGKZ      EFEMP2     ANTXR2     LAPTM5    PHACTR4    SNTB2
  MCM10     EIF4EBP1   ARHGAP17   LDB2      PLK2       SNX27
  MCM6      EZH2       ASPM       LDOC1     PNO1       SPIN1
  PCNA      FAM46A     BID        LMO4      PNP        SSSCA1
  RBPMS     HOXD10     BMP4       LRP1      PPIA       STXBP2
  RPS6KA1   HSPA4      BNIP2      LRP6      PPIH       SUB1
  SAT1      ITGB3BP    C1QA       LRRC41    PRPF18     TALDO1
  BUB1      KLF6       CBX4       LZTS2     PSMA6      TGFBR3
  CSNK1E    MAD2L2     CCNE1      MAGEH1    PSMB7      TNFRSF1A
  DCN       MAP2K4     CCR1       MELK      PSMD4      UFD1L
  FGFR1     MAPK10     CDC42BPA   MPDZ      PSME3      WSB2
  FXYD1     MCM5       CENPE      MTA1      PSMF1      XPNPEP1
  GMNN      MITF       CHFR       MYCBP     PSTPIP1    YLPM1
  HOXA10    MMP9       CIB1       MYL9      PTTG1      ZMIZ1

###### 

Driver genes identified by integrated analysis of the microarray datasets (cervical keratinized squamous cell carcinoma).

  Gene                                              
  -------- ---------- ---------- -------- --------- --------
  FYN      ADAM10     ARHGAP17   HSPB2    PHF1      TMOD1
  ZHX1     ADAM17     ARMCX2     ID4      PIK3C2B   TMSB10
  ABL1     ANXA6      BIN1       LDB2     PIP5K1C   TPD52
  BCL2L1   AXL        CBX3       LDOC1    PNP       UBTF
  FXR2     BCL11A     CLDN5      LMO4     PSME3     ZHX2
  TBP      CSNK1E     CNN3       LRP1     PSMF1     ZMIZ1
  AR       DMPK       CNNM3      LRP6     PTOV1     ZNF76
  BARD1    ITGB3BP    CNTNAP1    LSM5     PTPN12    
  BID      KPNA6      CRYAB      MAGI2    RAE1      
  DDX24    MAD2L2     CSE1L      MAPK10   REV3L     
  NCOA1    MCL1       CSTF1      MIS12    RUNX1T1   
  PDGFRB   NR2F1      EFEMP2     MPDZ     SDC2      
  PRKD1    NTRK2      EXOSC5     MTA1     SFRP1     
  PSEN1    PPP1R14A   FGFR1      MYCBP    SH3BP5    
  RBPMS    PTN        FXYD1      NPDC1    TAF9      
  SPTAN1   RTN3       FZD6       NR2F2    TCF7L2    
  TCF4     SYK        GAS6       NTF3     TERF1     
  TGFA     VIM        GDI1       NUDT21   TFDP1     
  A2M      ANTXR2     GTF3C3     PBX1     TGFBR3    
  ACP1     AQP1       HOXA10     PDGFD    TLN2      

###### 

Driver genes identified by integrated analysis of the microarray datasets (cervical adenocarcinoma G3).

  Gene                                               
  ---------- -------- ---------- --------- --------- --------
  CAV1       BAHD1    PPA1       CLDN5     MED14     SF1
  FLNA       C1QBP    PRKD1      CUL4B     MPDZ      SMO
  PPP1CA     CPSF6    SAT1       DMPK      MYL9      SPINT2
  NCK2       CSNK1D   SMAD1      EFNB1     NR2F1     SSBP3
  PLSCR1     DOCK1    SNAP23     F3        NTF3      SSR1
  SUMO4      DVL2     TAF1D      GDI1      PCGF2     STAM
  LMNA       FXR2     TAF9       HOXA10    PDPK1     SYNE1
  LRP1       FXYD1    TCF4       HOXD10    PHACTR4   TCF7L2
  PSEN1      ILK      WIPI1      HOXD13    PHYHIP    TGFBR3
  PTN        LDB1     ACVR2A     HSPA1B    PLSCR4    TMF1
  CSNK1E     LMO4     ANTXR2     HSPBAP1   PNPLA2    UBTF
  DVL3       MAP2K4   ATG12      KANK1     PPP1R10   VAMP8
  MMP14      NCOA1    CD82       KPNA6     PTCH2     WASF1
  PPP1R14A   NTRK2    CDC42BPA   LDB2      RNF138    WASF2
  ALDOA      PBX1     CDC42EP1   LRP6      RUNX1T1   ZHX1

###### 

Driver genes identified by integrated analysis of the microarray datasets (cervical non-keratinized squamous cell carcinoma).

  Gene                                             
  -------- -------- ---------- --------- --------- -----------
  AR       FXR2     FOXO1      TLR2      FBN2      NTF3
  ABL1     ILK      GMNN       TXNDC9    FGR       NTRK2
  CAV1     LMNA     HOXD10     XRCC4     FXYD1     NUBP1
  CHD3     MEIS1    ICAM3      YAP1      GDI1      PALLD
  HIF1A    NCOA1    ITGB2      ADCY6     HCLS1     PDPK1
  PTPN6    PAG1     LCP2       ADI1      HLA-DMB   PGK1
  SAT1     PBX1     LRP1       AGTPBP1   HLA-DRA   PGLS
  FLNA     PIAS1    MAFG       ANTXR2    HOXD13    PIK3R3
  HOXA10   PSEN1    MPDZ       ANXA6     HSPB2     PLTP
  PLSCR1   PTN      NDN        ARHGDIB   LCP1      PNP
  RAF1     WASF2    NR2F2      CDC37     LDOC1     PRRX1
  DCN      ZHX1     PAICS      CITED2    LILRB2    RAB11FIP2
  EZR      ACTR3    PLSCR4     CLDN5     LRP6      RAB18
  MMP14    BIN1     PPP1R14A   CNN3      MAPK10    RFXANK
  PDGFRB   C1QB     PPP2R1A    COL4A5    MED14     RUNX1T1
  ABCA1    C1QC     PRDX2      DOCK1     MTA1      SAT2
  C1QA     CSNK1D   SNTB2      DVL2      MYO5B     SEPHS1
  CSNK1E   DGKZ     SSSCA1     ENO1      NARF      SF1
  DMPK     DVL3     TCF4       FAM46A    NISCH     
  ELN      EFEMP2   TLR1       FBLN1     TICAM1    
  SNX2     SYNE1    TCF7L2     VTA1      TRAP1     
  TMEM8B   TMOD1    TMSB10     TPD52     SH3BP5    
  WASF3    ZNF76    TEAD3      TIMP2     NR2F1     

###### 

Driver genes identified by integrated analysis of the microarray datasets (cervical adenocarcinoma G2).

  Gene                                                
  -------- --------- ----------- ---------- --------- ----------
  ABL1     HSPA5     ASAP1       PSMF1      ASS1      EHD2
  AR       HTRA1     AXL         QKI        ATRX      ENAH
  CAV1     LMNA      BCR         RAB4A      AURKA     ENO1
  PPP1CA   MEIS1     BGN         RNF138     AURKB     ERBB3
  FLNA     NTRK2     BMP4        SDC2       BIN1      FBLN1
  FYN      PRNP      BRCA2       SMARCE1    BIRC5     GAS6
  MMP2     PTPN12    CDKN2A      SNAP29     CAPZB     GLRX3
  SMAD1    SMAD5     CSNK1E      TAF7       CAV2      GOLGA2
  NCK2     TAF9      DMPK        TCF4       CBX4      GTF2I
  RB1      TTF2      DOCK1       TGFBR3     CD81      HAT1
  PTN      DVL2      DR1         THBS2      CDT1      HOXD10
  PTPN6    EFEMP2    FGFR1       TIFA       CEP76     HSPA1B
  SMAD7    FXR2      FXYD1       TIMP2      CLDN5     HSPB2
  SUMO4    HOXA10    GDF5        TNFRSF1A   CLU       IDE
  A2M      HOXD13    GNA12       ZHX1       CNN3      IFI35
  AP1M1    LRP1      KIDINS220   ADI1       CNTNAP1   IFNAR1
  CDC5L    NCOA1     LDOC1       AHNAK      COL4A5    ILK
  EZR      NOTCH2    LRP6        ALDOA      COL6A3    IQGAP1
  MMP14    PBX1      MAFG        ANTXR1     COX5A     JAG1
  PIAS1    PDGFRB    MAP2K4      ANTXR2     CUL4B     KANK1
  CD2AP    PRKD1     MAPK10      ANXA6      CXCL12    KDM2A
  CDH1     SAT1      MEF2C       AQP1       DCLRE1A   KPNA6
  DCN      WASF2     POLE3       ARHGAP17   DDX24     LCAT
  DRAP1    YAP1      PPP1R14A    ARHGEF6    EFNB1     MAD2L1BP
  ELN      ACVR2A    PRRX1       ASH1L      EFS       MAP3K3
  MCM4     NR2F2     PLSCR4      RUNX1T1    SYNE1     WNK1
  MED14    NTF3      PPA1        SALL2      TEAD3     YLPM1
  MPDZ     NUDT21    PPP1R10     SAT2       TERF1     ZMIZ1
  MSN      PALB2     PPP2R1A     SETD7      THBS3     
  MYCBP2   PALLD     PSMB10      SH3BP5     TMEM8B    
  MYO5B    PBX3      PURA        SH3KBP1    TSPAN4    
  NFE2L1   PDGFD     RAB11FIP1   SKAP1      TWIST2    
  NMI      PHACTR4   RAB11FIP2   SPARCL1    UBTF      
  NPHS2    PIP4K2B   RBPJ        STX3       VGLL4     
  NR2F1    PKD2      REPS2       STX7       WFDC2     

###### 

Driver genes identified by integrated analysis of the microarray datasets (adenocarcinoma of the ovary Grade 2).

  Gene                                               
  -------- ---------- ---------- -------- ---------- ---------
  JUN      MEF2C      HSPA1A     CNNM3    GNE        PHF1
  FXR2     NCOA2      HTRA1      COX5A    GNG4       PKD2
  RAF1     NIF3L1     IKZF4      CRY2     GPRASP1    PLA2G16
  RBPMS    PCBD1      LIFR       CTF1     HMGA1      PLK1
  ZBTB16   PDGFRA     MAPK10     CTSD     HSPA2      PTPN13
  PRKACA   PRTFDC1    MYO15A     DCN      ICAM3      RBBP8
  CAV1     STAT5A     NFE2L1     DST      IGFBP4     RBP1
  MAP3K3   APBB1      NR2F6      ELF3     IRS1       SDC2
  MAP3K5   C1R        PER1       ELK1     KIAA1217   SGK1
  NCOA1    C1S        PTPN6      ENAH     MAFG       SH3BP5
  PDGFRB   CALCOCO2   SERPING1   ENG      MRAS       SMC3
  SIN3A    CD2AP      SIN3B      EPS8     NBL1       SNCA
  ABLIM1   DCTN1      TGFBR3     ETV6     NFATC4     SNRNP70
  DDX17    DMPK       TSC22D3    EYA2     NINL       SPOP
  FEZ1     DVL2       UBQLN1     FLAD1    NR2F2      SPTBN1
  GATA4    FHL2       ACTA2      FOXO1    OLFML3     SPTBN2
  GOLGA2   FLNA       BEGAIN     FOXO3    PAICS      ST13
  LRP1     FXYD1      CCT5       FTH1     PDGFD      STRBP
  TCF4     THRA       TPM2       TXN      USP13      ZC3H10
  TEAD1    TOP2A      TRIM21     TXNDC9   WTIP       ZFPM2

###### 

Driver genes identified by integrated analysis of the microarray datasets (adenocarcinoma of the ovary Grade 3).

  Gene                                             
  --------- --------- -------- ---------- -------- -------
  CDK1      HLA-DRA   CD14     FCGR2B     PDGFD    NR2F2
  AURKB     ICAM3     CDC20    FOS        SLPI     
  CAV1      KRT7      CDH1     GCA        SMC4     
  PTPN6     MAD2L1    CDKN2A   GNE        SOX9     
  ZBTB16    MAL2      CEBPG    GPRASP1    SPINT1   
  BCL2L1    MAP3K5    CENPA    HLA-DMB    ST14     
  HSPA1A    PDGFRA    CKS2     HLA-DRB1   STRBP    
  IRS1      PDGFRB    CLDN1    LAPTM5     TACC1    
  ITGB2     PMAIP1    CLDN3    LCP1       TOP2A    
  MCM2      RACGAP1   CRIP1    LRP1       TRIP13   
  NDC80     RBPMS     CTSS     MSLN       TYROBP   
  SYK       TPD52     CXCR4    MUC1       ZWINT    
  TPD52L1   ALOX5     DBF4     MUC16      ECT2     
  BCL11A    ALOX5AP   DSC2     NCAPD2     CCNB1    
  CCNB2     BIK       DSG2     NR2F1      ERBB3    

###### 

Driver genes identified by the integrated analysis of the microarray datasets (endometrial carcinoma).

  Gene                                              
  -------- ---------- --------- -------- ---------- ----------
  EP300    CDKN2A     F2R       AMFR     EPN3       MMP11
  JUN      COL3A1     FZD5      AXL      EPR1       MMP26
  CAV1     EGR1       HLA-DMB   BCL11A   FOSB       MYO5B
  CTNNB1   ERBB4      HOXA10    BCL2A1   GALNT10    NRG2
  ABL1     FBLN1      ID1       BIK      GAS6       NRXN2
  AR       FBN1       ID4       BLNK     GATA2      PCOLCE
  TCF4     FLNA       IDE       C1R      GCH1       PDGFRB
  THBS1    FOXO1      INADL     C1S      GCHFR      PKD2
  TUBA4A   HLA-DRA    JUND      C3AR1    GPI        PNP
  ATXN1    ID3        LMO4      CCND2    GPRASP1    PPP1R14A
  COL1A1   IGFBP5     LNX1      CDH11    HLA-DQB1   PRDM1
  DCN      LAMB3      NCALD     CDKN1A   HLA-DRB1   PSTPIP2
  LRP1     MITF       NCF2      CDKN2C   HLF        PTGDS
  C3       MYC        NR2F2     CFB      HOXA9      PTGS2
  COL7A1   PLAT       PDGFRA    CGN      ID2        R3HDM2
  FBLN2    RUNX1T1    PLEKHF2   CLEC3B   IGFBP4     RAB25
  FOS      S100A8     PTPN13    CLK1     IGFBP6     RAB3IP
  GNAI2    SERPINA1   RAB8B     CXADR    IL33       RAPGEF6
  IGF1     SYK        RABAC1    CXCL10   IRS1       S100A9
  LAMC2    TGFB1I1    ROR2      DNM1     KLF5       SCRIB
  MUC1     CD14       SFN       DPYSL2   LAPTM5     SEC24D
  NID1     COL5A1     SFRP1     ECM1     LDB2       SNTB2
  PRKD1    CRMP1      TFAP2A    EDNRA    LUC7L3     SOX9
  PTPN12   DBP        TJP2      EFEMP2   MAFB       SPINT1
  VCAN     DDR2       TRPC1     EFS      MAL2       SPP1
  CD74     F10        WNT5A     ENO2     MAPK10     ST14
  SYTL1    TJP3       TLR3      TRO      WASF2      WNT4
  TBL1X    TLR2       TPD52     USP54    WNT2       ZEB1
